SCHEMBL21069265

SCHEMBL21069265

COC(=O)c1nn(-c2ccc(C=O)cc2)cc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 4/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 2/20 0.46
MAPK1 P28482 2/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
SIRT6 Q8N6T7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18376210 0.85 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL1639488 0.84 GAA (0.57) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL21069235 0.82 MAPT (0.47) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL12800041 0.78 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL21071128 0.78 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL12800771 0.77 SMN1; SMN2 (0.62) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL21071090 0.73 SMN1; SMN2 (0.44) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL1558732 0.73 L3MBTL1 (0.60) ALDH1A1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL21069830 0.73 MAPT (0.63) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL21071214 0.73 POLB (0.46) KDM4EALDH1A1SMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 CN disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 EP disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885ALDH1A1 2776/4885SMN1; SMN2 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.